

[x](#)

## How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
  - For example, a search on Aminosalicyclic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
  - A search for “Aminosalicyclic Acid Tablets” will result in anything that specifically contains “Aminosalicyclic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
  - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:** You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
LEVODOPA	IMPURITIES	USP37–NF32	3533	25-Jul-2014	1-Aug-2014	USP39–NF34	First	Row 6 of

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Errata Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
								<i>Supplement to USP38–NF33</i>	Column 1 of Table 1: Change 1-Veratrylglycine to: L-Veratrylglycine <sup>a</sup> AND Add a footnote: <sup>a</sup> 3-(3,4-Dimethoxyphenyl)-L-alanine.
VINBLASTINE SULFATE	IDENTIFICATION N/B.	<i>USP37–NF32</i>	5150	25-Jul-2014		1-Aug-2014	<i>USP39–NF34</i>	<i>First Supplement to USP38–NF33</i>	Line 1 of Sample: Change 100 mg/mL in water to: 10 mg/mL in water
CEFADROXIL	ASSAY/ Procedure	<i>First Supplement to USP37–NF32</i>	6602	25-Jul-2014		1-Aug-2014	<i>USP39–NF34</i>	<i>First Supplement to USP38–NF33</i>	Line 3 of Sample solution: Change USP Cefadroxil RS to: Cefadroxil
METHODS	LIGHT OBSCURE	<i>USP37–NF32</i>	1301	25-Jul-2014		1-Aug-2014	<i>USP39–NF34</i>	<i>First</i>	Line 26 of

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
FOR THE DET ERMINATION OF PARTICULATE MATTER IN INJECTIONS AND OPHTHALMIC SOLUTIONS	RATION PARTICLE COUNT TEST/ <i>Instrument Standardization Tests/Particle Counting Accuracy—System Suitability</i>						<i>Supplement to USP38–NF33</i>	<i>Method 1—MWHC Instruments: Change <math>P_B</math> is the average particle count obtained from the suspension; to: <math>P_S</math> is the average particle count obtained from the suspension;</i> Line 2 of USP
TERBINAFINE HYDROCHLORIDE	ADDITIONAL REQUIREMENT S/USP <i>Reference Standards &lt;11&gt;</i>	<i>First Supplement to USP37–NF32</i>	6704	25-Jul-2014	1-Aug-2014	<i>USP39–NF34</i>	<i>First Supplement to USP38–NF33</i>	Terbinafine Related Compound A RS: Change <i>N</i> -Methyl-C -(naphthalen-1-yl)methanamine . to: <i>N</i> -Methyl-C -(naphthalen-1-yl)methanamine hydrochloride.

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>AND Line 2 of USP Terbinafine Related Compound B RS: Change (2Z)-N</p> <p>,</p> <p>6, 6-Tr imethyl-N -(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine.</p> <p>to: (2Z)-N</p> <p>,</p> <p>6, 6-Tr imethyl-N -(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine hydrochloride.</p> <p>AND Line 2 of USP Terbinafine Related Compound C: Change</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							(2E)-N , 6, 6-Tr imethyl-N -(naphthalen-2-ylmethyl)hept-2-en-4-yn-1-amine. to: (2E)-N , 6, 6-Tr imethyl-N -(naphthalen-2-ylmethyl)hept-2-en-4-yn-1-amine hydrochloride. AND Line 2 of Terbinafine Related Compound D RS: Change (2E)-N , 6, 6-Tr imethyl-N -[4-methylnaph

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
CEFTIZOXIME FOR INJECTION	Constituted solution	USP37–NF32	2240	25-Jul-2014		1-Aug-2014	USP39–NF34	First Supplement to USP38–NF33	<p>thalen-1-yl)methyl]hept-2-en-4-yn-1-amine. to: (2E)-N , 6, 6-Tr imethyl-N -[(4-methylnaphthalen-1-yl)methyl]hept-2-en-4-yn-1-amine hydrochloride.</p> <p>Line 1: Change At the time of use, it meets the requirements for <i>Constituted Solutions</i> under <i>Labeling</i> under <i>Injections</i> &lt;1&gt;. to: At the time of use, it meets the requirements for <i>Constituted Solutions</i> under <i>Injections</i> &lt;1&gt;.</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
DOXAPRAM H ASSAY/ YDROCHLORI Procedure DE INJECTION	USP37–NF32	2708	25-Jul-2014	1-Aug-2014	USP39–NF34	First Supplement to USP38–NF33	Line 7 of Analysis: Change $R_U$ = peak response ratio of the doxapram to the internal standard from the <i>Sample solution</i> $R_S$ = peak response ratio of the doxapram to the internal standard from the <i>Sample solution</i> to: $R_U$ = peak response ratio of doxapram to the internal standard from the <i>Sample solution</i> $R_S$ = peak response ratio of doxapram to the internal standard from the <i>Standard</i>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
LEFLUNOMIDE IM PUR ITIES/ <i>Organic Impurities/Procedure 2</i>	USP37–NF32	3502	25-Jul-2014	1-Aug-2014	USP39–NF34	First Supplement to USP38–NF33	<i>solution</i> Line 3 of <i>Analysis:</i> Change [Note—Disregard any peak with an area less than the leflunomide peak from the <i>System suitability solution.</i> to: [Note—Disregard any peak with an area less than the leflunomide peak from the <i>Sensitivity solution.</i>
NALTREXONE Assay HYDROCHLORIDE	USP37–NF32	3922	25-Jul-2014	1-Aug-2014	USP39–NF34	First Supplement to USP38–NF33	Line 7 of <i>Procedure:</i> Change (377.86/341.41) $10C(r_U/r_S)$ in which 377.86 and 341.41 are the molecular weights of

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
VITAMIN E ASSAY	ASSAY/ Procedure 4/ Chromatographic system	<i>First Supplement to USP37–NF32</i>	6338	25-Jul-2014		1-Aug-2014	<i>USP39–NF34</i>	<i>First Supplement to USP38–NF33</i>	naltrexone hydrochloride and naltrexone to: (377.86/341.40) 10C( $r_U/r_S$ ) in which 377.86 and 341.40 are the molecular weights of naltrexone hydrochloride and naltrexone Line 1 of <i>Flow rate</i> : Change 1.5 mL/min to: 1 mL/min
GENERAL NOTICES TO USP-NF	6. TESTING PRACTICES AND PROCEDURES/6.50. <i>Preparation of Solutions</i>	<i>First Supplement to USP37–NF32</i>	6291	25-Jul-2014		1-Aug-2014	<i>USP38–NF33</i>	<i>USP38–NF33</i>	Line 6 of 6.50.20. <i>Solutions</i> : Change An expression such as “(1 in 10)” means that 1 part <i>by volume</i> of a liquid shall be diluted with a sufficient quantity of the

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>diluent or solvent to make the volume of the finished solution 10 parts <i>by volume</i>. An expression such as “(20:5:2)” means that the respective numbers of parts, by volume, of the designated liquids shall be mixed, unless otherwise indicated.</p> <p>to:</p> <p>An expression such as “(1 in 10)” means that 1 part <i>by volume</i> of a liquid shall be diluted with, or 1 part <i>by weight</i> of a solid shall be dissolved in, a sufficient</p>

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
									quantity of the diluent or solvent to make the volume of the finished solution 10 parts <i>by volume</i> . An expression such as "(20:5:2)" means that the respective numbers of parts, by volume, of the designated liquids shall be mixed, unless otherwise indicated.
SUFENTANIL CITRATE	ASSAY/ Procedure/Syst em suitability/S uitability requirements	<i>First Supplement to USP37–NF32</i>	6701	25-Jul-2014		1-Aug-2014	<i>USP39–NF34</i>	<i>First Supplement to USP38–NF33</i>	Line 1 of <i>Relative standard deviation</i> : Change NMT 0.7% to: NMT 0.73%
BUMETANIDE	IMPURITIES	<i>USP37–NF32</i>	2024	25-Jul-2014		1-Aug-2014	<i>USP39–NF34</i>	<i>First Supplement to USP38–NF33</i>	Row 4 of Column 1 of <i>Table 1</i> :

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
ROPINIROLE HYDROCHLORIDE	HIM PURITIES/Organic Impurities, Procedure 1/System suitability/Suitability requirements	<i>Revision Bulletin (Official May 01, 2014)</i>	Online	25-Jul-2014		1-Aug-2014	<i>USP39–NF34</i>	<i>First Supplement to USP38–NF33</i>	Change Paroxetine butyl 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoate to: Butyl 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoate Line 1 of <i>Tailing factor</i> : Change NLT 2.0 for the ropinirole peak to: NMT 2.0 for the ropinirole peak
CHLORDIAZEPoxide Hydrochloride for Injection	<i>Constituted solution</i>	<i>USP37–NF32</i>	2290	25-Jul-2014		1-Aug-2014	<i>USP39–NF34</i>	<i>First Supplement to USP38–NF33</i>	Line 1: Change At the time of use, it meets the requirements for <i>Constituted Solutions</i> under <i>Labeling</i> under <i>Injections &lt;1&gt;</i> . to: At the time of use, it meets the

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
ERGOTAMINE TARTRATE	Identification	USP37–NF32	2826	25-Jul-2014		1-Aug-2014	USP39–NF34	First Supplement to USP38–NF33	requirements for <i>Constituted Solutions</i> under <i>Injections &lt;1&gt;</i> . Line 4: Change value as the principal spot of <i>Standard solution A</i> . to: values as the corresponding spots of the <i>Standard preparation</i> .
LEVOTHYROXINE SODIUM TABLETS	PURITIES/ <i>Organic Impurities/Procedure: Limit of Liothyronine Sodium</i>	USP37–NF32	3548	25-Jul-2014		1-Aug-2014	USP39–NF34	First Supplement to USP38–NF33	Line 1 of <i>Acceptance criteria</i> : Change NMT 2.0% of liothyronine to: NMT 2.0% of liothyronine sodium
VITAMIN E	IDENTIFICATION N/A./ <i>Sample solutions</i>	USP37–NF32	5163	25-Jul-2014		1-Aug-2014	USP39–NF34	First Supplement to USP38–NF33	Lines 4 and 7 of <i>Alpha tocopheryl acetate</i> : Change dilute sulfuric acid

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
CEFADROXIL CAPSULES	ADDITIONAL REQUIREMENT S/USP Reference Standards <11>	<i>First Supplement to USP37–NF32</i>	6604	25-Jul-2014		1-Aug-2014	<i>USP39–NF34</i>	<i>First Supplement to USP38–NF33</i>	to: diluted sulfuric acid Line 2 of USP Cefadroxil Related Compound I RS: Change (6 <i>R</i> ,7 <i>R</i> )-7-[( <i>R</i> )-2-Amino-2-(4-hydroxyphenyl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate. to: (6 <i>R</i> ,7 <i>R</i> )-7-[( <i>R</i> )-2-Amino-2-(4-hydroxyphenyl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid. Line 2 of USP
ALLOPURINOL	<i>USP Reference</i>	<i>USP37–NF32</i>	1649	25-Jul-2014		1-Aug-2014	<i>USP39–NF34</i>	<i>First</i>	Line 2 of USP

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Errata Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
		<i>standards &lt;11&gt;</i>						<i>Supplement to USP38–NF33</i>	Allopurinol Related Compound C RS: Change <i>N</i> -(4 <i>H</i> -1,2,4-Triazol-4-yl)-1 <i>H</i> -pyrazole-4-carboxamide. to: 5-(4 <i>H</i> -1,2,4-Triazol-4-yl)-1 <i>H</i> -pyrazole-4-carboxamide.
RISPERIDONE ORAL SOLUTION	ADDITIONAL REQUIREMENT S/USP Reference Standards <11>	<i>Second Supplement to USP37–NF32</i>	Online	25-Jul-2014		1-Aug-2014	<i>USP39–NF34</i>	<i>First Supplement to USP38–NF33</i>	Line 2 of USP Risperidone Related Compounds Mixture RS: Change Contains a mixture of the following four compounds: 98.9% of <i>Risperidone</i> . 0.5% of <i>Risperidone cis-N-oxide: cis</i> -3-[2-[4-(6-Fluor

<a href="#">Monograph TitleSection</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>o-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-N-oxide.  0.3% of <i>Bicyclorisperidone</i>: 3-(4-Fluoro-2-hydroxyphenyl)-1-[2-(6,7,8,9-tetrahydro-2-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl)ethyl]-1-aza-2-azoniabicyclo[2.2.2]oct-2-ene iodide.  0.3% of <i>Z-Oxime</i>: (Z)-3-[2-[4-(2,4-Dif</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>luorophenyl)(hydroxyimino)methyl]-1-piperidinylethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one</p> <p>.</p> <p>to:</p> <p>Contains a mixture of the following four compounds:</p> <p>Risperidone.</p> <p>Risperidone <i>cis-N</i>-oxide:</p> <p><i>cis</i>-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinylethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one, <i>N</i>-oxide.</p> <p>Bicyclorisperido</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
CEFTRIAXONE Assay INJECTION	USP37–NF32	2241	25-Jul-2014	1-Aug-2014	USP39–NF34	First Supplement to USP38–NF33	<p>ne: 3-(4-Fluoro-2-hydroxyphenyl)-1-[2-(6,7,8,9-tetrahydro-2-methyl-4-oxo-4H-pyridido[1,2-a]pyrimidin-3-yl)ethyl]-2-aza-1-azoniabicyclo[2.2.2]oct-2-ene iodide.</p> <p>Z-Oxime: (Z)-3-[2-[4-(2,4-Difluorophenyl)(hydroxyimino)methyl]-1-piperidinyloxyethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyridido[1,2-a]pyrimidin-4-one</p> <p>Change pH 7.0 Buffer, pH 5.0 Buffer, Mobile phase,</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p><i>Standard preparation, Resolution solution, and Chromatographic system</i>—Prepare as directed in the Assay under <i>Ceftriaxone Sodium</i>.</p> <p>to:</p> <p><i>pH 7.0 Buffer</i>—Dissolve 13.6 g of dibasic potassium phosphate and 4.0 g of monobasic potassium phosphate in water to obtain 1000 mL of solution. Adjust this solution with phosphoric acid or 10 N potassium hydroxide to a pH of 7.0 ± 0.1.</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p><i>pH 5.0 Buffer</i>—Dissolve 25.8 g of sodium citrate in 500 mL of water, adjust with citric acid solution (1 in 5) to a pH of 5.0 ± 0.1, and dilute with water to a volume of 1000 mL.</p> <p><i>Mobile phase</i>—Dissolve 3.2 g of tetraethylammonium bromide in 400 mL of acetonitrile, add 44 mL of <i>pH 7.0 Buffer</i> and 4 mL of <i>pH 5.0 Buffer</i>, and add water to make 1000 mL. Pass through a membrane filter of 0.5-µm or finer porosity, and degas.</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>Make adjustments if necessary (see <i>System Suitability</i> under <i>Chromatography</i> &lt;621&gt;). <i>Standard preparation</i></p> <p>—Dissolve an accurately weighed quantity of USP Ceftriaxone Sodium RS in <i>Mobile phase</i> to obtain a solution having a known concentration of about 0.2 mg per mL. Use this solution promptly after preparation. <i>Resolution solution</i></p> <p>—Dissolve a suitable quantity of USP</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>Ceftriaxone Sodium <i>E</i>-Isomer RS in <i>Standard preparation</i>, and dilute with <i>Mobile phase</i> to obtain a solution containing about 160 µg of USP</p> <p>Ceftriaxone Sodium <i>E</i>-Isomer RS per mL and 160 µg of USP</p> <p>Ceftriaxone Sodium RS per mL. Use this solution promptly after preparation. <i>Chromatographic system</i> (see <i>Chromatography</i> &lt;621&gt;)—The liquid chromatograph is equipped with a 270-nm</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>detector and a 4.0-mm x 15-cm column that contains 5-?m packing L1. The flow rate is about 2 mL per minute. Chromatograph the <i>Resolution solution</i>, and record the peak responses as directed for <i>Procedure</i>. The resolution, <i>R</i>, between the ceftriaxone <i>E</i>-isomer and ceftriaxone peaks is not less than 3. Chromatograph the <i>Standard preparation</i>, and record the peak responses as directed under <i>Procedure</i>. The column</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>efficiency determined from the analyte peak is not less than 1500 theoretical plates, the tailing factor for the analyte is not more than 2, and the relative standard deviation for replicate injections is not more than 2%. AND</p> <p>Change <i>Procedure</i>—Proceed as directed for <i>Procedure</i> in the Assay under <i>Ceftriaxone Sodium</i>. Calculate the quantity, in mg, of ceftriaxone (C<sub>18</sub>H<sub>18</sub>N<sub>8</sub>O<sub>7</sub>S<sub>3</sub>) in each mL of</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>the Injection taken by the formula:</p> $200(C/V)(r_U/r_S)$ <p>in which <i>V</i> is the volume, in mL, of Injection taken; and the other terms are as defined therein.</p> <p>to:</p> <p><i>Procedure</i></p> <p>—Separately inject equal volumes (about 20 µL) of the <i>Standard preparation</i> and the <i>Assay preparation</i> into the chromatograph, record the chromatograms, and measure the responses for the major peaks.</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
DOXEPIN HYD PERFORMANC	USP37–NF32	2712	25-Jul-2014	1-Aug-2014	USP39–NF34	First	<p>Calculate the quantity, in mg, of ceftriaxone (<math>C_{18}H_{18}N_8O_7S_3</math>) in each mL of Injection taken by the formula:</p> $200(C/V)(r_U/r_S)$ <p>in which C is the concentration, in mg per mL, of USP Ceftriaxone Sodium RS in the <i>Standard preparation</i>; V is the volume, in mL, of Injection taken; and <math>r_U</math> and <math>r_S</math> are the ceftriaxone peak responses obtained from the <i>Assay preparation</i> and the <i>Standard preparation</i>, respectively. Change</p>

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
ROCHLORIDE	E TESTS CAPSULES							<i>Supplement to USP38–NF33</i>	<i>Uniformity of Dosage Units, Content Uniformity &lt;905&gt;</i> to: <i>Uniformity of Dosage Units &lt;905&gt;</i> : Meet the requirements The following procedure is used where the test for <i>Content Uniformity</i> is required. <i>Procedure for Content Uniformity</i> AND Delete a subsection: <i>Acceptance criteria</i> : Meet the requirements Line 2 of USP Levalbuterol Related Compound H
LEVALBUTEROL HYDROCHLORIDE	ADDITIONAL REQUIREMENT S/USP Reference	USP37–NF32	3513	25-Jul-2014		1-Aug-2014	USP39–NF34	<i>First Supplement to USP38–NF33</i>	

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
<i>Standards &lt;11&gt;</i>									
TICLOPIDINE HYDROCHLORIDE	IMPURITIES	USP37–NF32	4958	25-Jul-2014		1-Aug-2014	USP39–NF34	First Supplement to USP38–NF33	RS: Change 4-[2-( <i>tert</i> -Butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol. C <sub>14</sub> H <sub>23</sub> NO <sub>3</sub> 253.34 to: 4-[2-( <i>tert</i> -Butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol acetate. C <sub>14</sub> H <sub>23</sub> NO <sub>3</sub> · C <sub>2</sub> H <sub>4</sub> O <sub>2</sub> 313.39 Change Residue on Ignition <231> to: Residue on Ignition <281>
ATROPINE SULFATE	ASSAY/ Procedure/System suitability/Suitability requirements	First Supplement to USP37–NF32	6591	25-Jul-2014		1-Aug-2014	USP39–NF34	First Supplement to USP38–NF33	Line 1 of Relative standard deviation: Change NMT 1.0 to: NMT 1.0% Line 1 of
PHARMACEU	DEFINITIONS	USP37–NF32	403	25-Jul-2014		1-Aug-2014	USP39–NF34	First	Line 1 of

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
TICAL COMPOUNDING—NON STERILE PREPARATIONS						<i>Supplement to USP38–NF33</i>	<i>Beyond-Use Date (BUD):</i> Change The date after which a compounded preparation should not to be used; to: The date after which a compounded preparation shall not be used;
TERBINAFINE IMPURITIES HYDROCHLORIDE	<i>First Supplement to USP37–NF32</i>	6704	25-Jul-2014	1-Aug-2014	<i>USP39–NF34</i>	<i>First Supplement to USP38–NF33</i>	Footnotes b, c, and d of <i>Table 2</i> : Change <sup>b</sup> <i>trans</i> -Isoterbinafine or ( <i>E</i> )- <i>N</i> ,6,6-trimethyl- <i>N</i> -(naphthalen-2-ylmethyl)hept-2-en-4-yn-1-amine. <sup>c</sup> <i>cis</i> -Terbinafine

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>or (<i>Z</i>)-<i>N</i>,6,6-trimethyl-<i>N</i>-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine. d</p> <p>4-Methylterbinafine or (<i>E</i>)-<i>N</i>,6,6-trimethyl-<i>N</i>-((4-methylnaphthalen-1-yl)methyl)hept-2-en-4-yn-1-amine. to: <sup>b</sup><i>trans</i>-Isoterbinafine or (<i>2E</i>)-<i>N</i>,6,6-Trimethyl-<i>N</i>-(naphthalen-2-ylmethyl)hept-2-</p>

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
CEFAZOLIN INJECTION	Assay	USP37–NF32	2190	25-Jul-2014		1-Aug-2014	USP39–NF34	First Supplement to USP38–NF33	en-4-yn-1-amine. c cis-Terbinafine or (2Z)-N , 6, 6-Tr imethyl-N -(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine. e. d 4-Methylterbinafine or (2E)-N , 6, 6-Tr imethyl-N -((4-methylnaphthalen-1-yl)methyl)hept-2-en-4-yn-1-amine. Change pH 3.6 Buffer, pH 7.0 Buffer, Mobile phase, Internal standard

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p><i>solution, Standard preparation, and Chromatographic system—Prepare as directed in the Assay under Cefazolin.</i></p> <p>to:</p> <p><i>pH 3.6 Buffer—Dissolve 0.900 g of anhydrous dibasic sodium phosphate and 1.298 g of citric acid monohydrate in water to make 1000 mL.</i></p> <p><i>pH 7.0 Buffer—Dissolve 5.68 g of anhydrous dibasic sodium phosphate and 3.63 g of monobasic potassium</i></p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>phosphate in water to make 1000 mL.</p> <p><i>Mobile phase</i>—Prepare a suitable mixture of <i>pH 3.6 Buffer</i> and acetonitrile (9:1). Pass through a membrane filter having a 10-<math>\mu</math>m or finer porosity, and degas. Make adjustments if necessary (see <i>System Suitability</i> under <i>Chromatography</i> &lt;621&gt;).</p> <p><i>Internal standard solution</i></p> <p>—Transfer 750 mg of salicylic acid to a 100-mL volumetric flask, dissolve in 10</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>mL of methanol, dilute with <i>pH 7.0 Buffer</i> to volume, and mix.</p> <p><i>Standard preparation</i></p> <p>—Transfer about 25 mg of USP Cefazolin RS, accurately weighed, to a 25-mL volumetric flask, dissolve in and dilute with <i>pH 7.0 Buffer</i> to volume, and mix. Transfer 5.0 mL of this solution to a 100-mL volumetric flask, add 5.0 mL of <i>Internal standard solution</i>, dilute with <i>pH 7.0 Buffer</i> to volume, and</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>mix.</p> <p><i>Chromatographic system (see Chromatography &lt;621&gt;)</i>—The liquid chromatograph is equipped with a 254-nm detector and a 4.0-mm x 30-cm column that contains 10-<math>\mu</math>m packing L1. The flow rate is about 2 mL per minute. Chromatograph the <i>Standard preparation</i>, and record the peak responses as directed for <i>Procedure</i>. The relative retention times are about 0.7 for salicylic acid and 1.0 for cefazolin; the resolution, <i>R</i>,</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>between the analyte and internal standard peaks is not less than 4.0; the column efficiency is not less than 1500 theoretical plates; the tailing factor is not more than 1.5; and the relative standard deviation for replicate injections is not more than 2.0%.</p> <p>AND</p> <p>Change <i>Procedure</i>—Proceed as directed for <i>Procedure</i> in the <i>Assay</i> under <i>Cefazolin</i>. Calculate the quantity, in mg, of cefazolin</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>(C<sub>14</sub>H<sub>14</sub>N<sub>8</sub>O<sub>4</sub>S<sub>3</sub>)  in each mL of  the Injection  taken by the  formula:  <math>(1000C / V)(R_U / R_S)</math>  in which V is the  volume, in mL,  of Injection  taken, and the  other terms are  as defined  therein.  to:  <i>Proce  dure</i>  —Separately  inject equal  volumes (about  10 ?L) of the  <i>Standard  preparation</i> and  the <i>Assay  preparation</i> into  the  chromatograph,  record the  chromatograms,  and measure  the responses</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>for the major peaks.</p> <p>Calculate the quantity, in mg, of cefazolin (<math>C_{14}H_{14}N_8O_4S_3</math>) in each mL of Injection taken by the formula:</p> $(1000C / V)(R_U / R_S)$ <p>in which C is the concentration, in mg per mL, of USP Cefazolin RS, calculated on the anhydrous basis, in the <i>Standard preparation</i>; V is the volume, in mL, of Injection taken; and <math>R_U</math> and <math>R_S</math> are the peak response ratios of cefazolin to the internal standard</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
CLOPIDOGREL ASSAY/ BISULFATE <i>Procedure</i>	USP37–NF32	2422	25-Jul-2014	1-Aug-2014	USP39–NF34	<i>First Supplement to USP38–NF33</i>	obtained from the Assay preparation and the Standard preparation, respectively. Line 1 of System suitability solution: Change 25 µg/mL of USP Clopidogrel Bisulfate RS and 50 µg/mL of USP Clopidogrel Related Compound B RS to: 2.5 µg/mL of USP Clopidogrel Bisulfate RS and 5.0 µg/mL of USP Clopidogrel Related Compound B

<a href="#">Monograph TitleSection</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
FLAVOXATE H IMPURITIES YDROCHLORI DE	USP37–NF32	2988	25-Jul-2014	1-Aug-2014	USP39–NF34	First Supplement to USP38–NF33	RS Row 3 of Column 1 of <i>Impurity Table 1</i> : Change Flavoxate related compound A <sup>a,*</sup> to: Flavoxate related compound A <sup>a</sup> AND Row 4 of Column 1 of <i>Impurity Table 1</i> : Change Flavoxate related compound B <sup>b,*</sup> to: Flavoxate related compound B <sup>b</sup> AND Row 5 of Column 1 of <i>Impurity Table 1</i> : Change Flavoxate related

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
									compound C <sup>c,*</sup> to: Flavoxate related compound C <sup>c</sup> AND Delete footnote *
MITOTANE TABLETS	Assay	USP37–NF32	3858	25-Jul-2014		1-Aug-2014	USP39–NF34	<i>First Supplement to USP38–NF33</i>	Line 1 of <i>Procedure</i> : Change Proceed as directed in the Assay under <i>Mitotane</i> , beginning with “Concomitantly determine the absorbances of both solutions.” to: Concomitantly determine the absorbances of the Assay <i>preparation</i> and the <i>Standard preparation</i> in 1-cm cells at the wavelength

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>of maximum absorbance at about 268 nm, with a suitable spectrophotometer, using methanol as the blank.</p> <p>Calculate the quantity, in mg, of C<sub>14</sub>H<sub>10</sub>Cl<sub>4</sub> in the portion of Tablets taken by the formula:  <math>0.5C(A_U/A_S)</math>  in which C is the concentration, in mg/mL, of USP Mitotane RS in the <i>Standard preparation</i>, and A<sub>U</sub> and A<sub>S</sub> are the absorbances of the <i>Assay preparation</i> and the <i>Standard preparation</i>, respectively.</p>

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
GELATIN	SPECIFIC TESTS/ <i>Sulfur Dioxide/ Analysis</i>	<i>USP37–NF32</i>	5995	25-Jul-2014		1-Aug-2014	<i>USP39–NF34</i>	<i>First Supplement to USP38–NF33</i>	Line 5 of the variable definition list: Change <i>m</i> = actual molarity of the <i>Titrant</i> (mol/mL) to: <i>m</i> = actual molarity of the <i>Titrant</i> (mol/L)
INSULIN ASPART	IDENTIFICATION/ <i>N/B. Physicochemical Analytical Procedures for Insulins, Peptide Mapping &lt;121.1 &gt;/Chromatographic system</i>	<i>First Supplement to USP37–NF32</i>	6647	25-Jul-2014		1-Aug-2014	<i>USP39–NF34</i>	<i>First Supplement to USP38–NF33</i>	Line 1 of <i>Column</i> : Change 4.0-mm x 25-cm; 5-µm packing L7 to: 4.6-mm x 10-cm; 3-µm packing L1
AMIODARONE HYDROCHLORIDE	IMPURITIES/ <i>Organic Impurities/Procedure 1</i>	<i>USP37–NF32</i>	1750	30-May-2014		1-Jun-2014	<i>USP38–NF33</i>	<i>USP38–NF33</i>	Line 3 of <i>Acceptance criteria</i> : Change <i>Standard solution B</i> is not more intense to: the <i>Sample solution</i> is not more intense

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Errata Sort Date</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
QUINIDINE GLUCONATE XTENDED- RELEASE TABLETS	ASSAY/ E <i>Procedure</i>	USP37–NF32	4515	30-May-2014		1-Jun-2014	USP38–NF33	USP38–NF33	Line 2 of <i>System suitability solution:</i> Change dihydroquinidine chloride to: dihydroquinidine hydrochloride
DAPSONE TABLETS	IDENTIFICATION N/B. <i>Ultraviolet Absorption</i> <197U>	USP37–NF32	2514	30-May-2014		1-Jun-2014	USP38–NF33	USP38–NF33	Line 1 of <i>Sample solution:</i> Delete Nominally 0.01 ?g/mL prepared as follows.
SULFACETAMIDE OF SODIUM OPHTHALMIC OINTMENT	ASSAY/ <i>Procedure</i>	USP37–NF32	4765	30-May-2014		1-Jun-2014	USP38–NF33	USP38–NF33	Line 1 of <i>Sample solution:</i> Change USP Sulfacetamide Sodium RS to: sulfacetamide sodium
GADOPENTETATE DIMEGLUMINE INJECTION	IDENTIFICATION N/B.	USP37–NF32	3113	30-May-2014		1-Jun-2014	USP38–NF33	USP38–NF33	Line 2: Change 364.8 nm to: 368.4 nm

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
VALSARTAN	IMPURITIES	USP37–NF32	5115	30-May-2014		1-Jun-2014	USP38–NF33	USP38–NF33	Footnote a of <i>Table 1</i> : Change (S)-N-Butyryl-N-([2?-(1H-tetrazole-5-yl)bi phen-4-yl]methyl)-valine. to: N-Butyryl-N-([2?-(1H-tetrazole-5-yl)bi phenyl-4-yl]methyl)-L-valine. AND Footnote b of <i>Table 1</i> : Change (S)-N-Valeryl-N-([2?-(1H-tetrazole-5-yl)bi phen-4-yl]methyl)-valine benzyl ester. to:

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
STRONG IODINE SOLUTION	ASSAY	USP37–NF32	3354	30-May-2014		1-Jun-2014	USP38–NF33	USP38–NF33	<p><i>N</i> -Valeryl -<i>N</i> -{[2?-(1<i>H</i> -tetrazole-5-yl)bi phenyl-4-yl]met hyl}-L-valine benzyl ester.</p> <p>Line 1 of <i>Acceptance criteria</i> in <i>Iodine</i>: Change of iodine (I) to: of iodine (I) in each 100 mL AND Line 1 of <i>Acceptance criteria</i> in <i>Potassium Iodide</i>: Change potassium iodide (KI) to: potassium iodide (KI) in each 100 mL</p>
ECHINACEA PALLIDA	ADDITIONAL REQUIREMENT S/USP	USP37–NF32	5353	30-May-2014		1-Jun-2014	USP38–NF33	USP38–NF33	Line 5: Change USP Powdered <i>Echinacea</i>

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
		<i>Reference Standards &lt;11&gt;</i>							<i>purpurea Extract RS to: USP Powdered Echinacea pallida Extract RS</i>
MICONAZOLE INJECTION	IDENTIFICATION N/A./ <i>Chromatographic system</i>	USP37–NF32	3831	30-May-2014		1-Jun-2014	USP38–NF33	USP38–NF33	Line 1 of <i>Spray reagent</i> . Change (Dragendorff's reagent) to: (Dragendorff's TS)
POWDERED D ECAFFEINATE TESTS D GREEN TEA EXTRACT		USP37–NF32	5438	30-May-2014		1-Jun-2014	USP38–NF33	USP38–NF33	Line 5 of <i>Analysis in Limit of Gallic Acid</i> : Change Separately calculate the percentages of gallic acid to: Calculate the percentage of gallic acid AND Line 5 of <i>Analysis in Limit of Caffeine</i> :

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
DESCRIPTION AND SOLUBILITY	<i>Racemethionine</i>	USP37–NF32	1523	30-May-2014		1-Jun-2014	USP38–NF33	USP38–NF33	Change Separately calculate the percentages of caffeine to: Calculate the percentage of caffeine Line 6: Change flavors and fragrance. to: flavors and fragrance.
OXCARBAZEPINE TABLETS	PERFORMANCE TESTS/ <i>Dissolution</i> <711>/Test 2	USP37–NF32	4119	30-May-2014		1-Jun-2014	USP38–NF33	USP38–NF33	Line 4 of <i>Standard solution</i> : Change µg/mL, where <i>L</i> is the label claim in mg/Tablet. to: mg/mL, where <i>L</i> is the label claim in mg/Tablet.
ATROPINE SULFATE	IMPURITIES	<i>First Supplement to USP37–NF32</i>	6591	30-May-2014		1-Jun-2014	USP38–NF33	USP38–NF33	Row 6 of Column 1 of <i>Table 2</i> :

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							Change Hyoscyamine related compound A <sup>e</sup> to: Hyoscyamine related compound A AND Delete footnote e AND Reletter the following footnotes in both the table and footnote definitions: f to e g to f
ALUMINUM CH ASSAY/ LOROHYDRAT <i>Procedure 4</i> E SOLUTION	USP37–NF32	1686	30-May-2014	1-Jun-2014	USP38–NF33	USP38–NF33	Line 2 of <i>Analysis</i> : Change anhydrous aluminum dichlorohydrate to: anhydrous aluminum chlorohydrate
PYRAZINAMID <i>Identification/B</i> :	USP37–NF32	4493	30-May-2014	1-Jun-2014	USP38–NF33	USP38–NF33	Line 4: Change

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
E	<i>Ultraviolet Absorption</i>								on the dried basis to: on the anhydrous basis
CHLOROXYLE NOL	IM PURITIES/ <i>Organic Impurities</i>	USP37–NF32	2308	30-May-2014		1-Jun-2014	USP38–NF33	USP38–NF33	Line 12 of <i>Analysis:</i> Change $C_S =$ concentration of 3,5-dimethylphenol or chloroxylenol related compound A in the <i>Standard solution</i> (mg/mL) to: $C_S =$ concentration of 3,5-dimethylphenol or USP Chloroxylenol Related Compound A RS in the <i>Standard solution</i> (mg/mL)

---

## Pagination

- [\\_ First page « First](#)
- [\\_ Previous page ‹ Previous](#)
- ...
- [\\_ Page 28](#)
- [\\_ Page 29](#)
- [\\_ Page 30](#)
- [\\_ Page 31](#)
- [\\_ Page 32](#)
- [\\_ Page 33](#)
- [\\_ Page 34](#)
- [\\_ Page 35](#)
- [\\_ Page 36](#)
- ...
- [\\_ Next page Next ›](#)
- [\\_ Last page Last »](#)